Search
for
Sort by
Research 30 of 1000+
- Physiology of the Hypothalamic Pituitary Gonadal Axis in the Male
- Replacement with GABAergic steroid precursors restores the acute ethanol withdrawal profile in adrenalectomy/gonadectomy mice
- COVID-19 pandemic: what about the gonads?
- Gonadal Dysgenesis: Associations between Clinical Features and Sex of Rearing.
- Three-Dimensional Analysis of Sex- and Gonadal Status- Dependent Microglial Activation in a Mouse Model of Parkinson’s Disease
- Role of Environmental Factors and Gonadotoxin Exposure in Unexplained Male Infertility
- Gonadal Sex Steroids: Production, Action and Interactions in Mammals
- Adrenal and Gonadal Activity, Androgen Concentrations, and Adult Height Outcomes in Boys With Silver-Russell Syndrome
- Gonads
- Coconut oil works as a gonadal feedback testosterone booster and increases pituitary aromatase (cyp19a1b) expression levels in fugu (Takifugu rubripes)
- Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome.
- Sex differences in the hypothalamic–pituitary–adrenal axis’ response to stress: an important role for gonadal hormones
- Gonadal Function Abnormalities in Sickle Cell Anemia
- Clinical and Hormonal Effects of Chronic Gonadotropin Releasing Hormone Agonist Treatment in Polycystic Ovarian Disease*
- Puberty in Boys: Correlation of Plasma Levels of Gonadotropins (LH, FSH), Androgens (Testosterone, Androstenedione, Dehydroepiandrosterone and Its Sulfate), Estrogens (Estrone and Estradiol) and Progestins (Progesterone and 17-Hydroxyprogesterone)
- Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5<i>α</i>-Reductase Activity and Androgen Receptor Content*
- Treatment of Hirsutism with a Gonadotropin-Releasing Hormone Agonist (Nafarelin)∗
- Female Gonadal Function before and after Treatment of Acromegaly
- Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism.
- Effects of the 5α-Reductase Inhibitor Finasteride on Serum Levels of Gonadal, Adrenal, and Hypophyseal Hormones and its Clinical Significance: A Prospective Clinical Study
- Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission
- Gonadal dysgenesis and bone metabolism
- 17-Hydroxyprogesterone Responses to Gonadotropin-Releasing Hormone Disclose Distinct Phenotypes of Functional Ovarian Hyperandrogenism and Polycystic Ovary Syndrome
- The Aromatase Inhibitor Fadrozole and the 5-Reductase Inhibitor Finasteride Affect Gonadal Differentiation and Gene Expression in the Frog <i>Silurana tropicalis</i>
- Gonadotropin-Releasing Hormone Agonist Treatment in Postmenopausal Women with Hyperandrogenism of Ovarian Origin
- The effect of treatment with an LH-RH agonist (Buserelin) on gonadal activity growth and bone maturation in children with central precocious puberty
- Melanocyte and gonad activity as potential severity modifying factors in C3H/HeJ mouse alopecia areata
- Gonadal Suppressive and Cross‐Sex Hormone Therapy for Gender Dysphoria in Adolescents and Adults
- Gonadotropin releasing hormone agonist (nafarelin) test to differentiate gonadotropin deficiency from constitutionally delayed puberty in teen-age boys--a clinical research center study.
- Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women.